JOINN - Announcement on the results of shareholder reduction of shares held by Beijing Zhaoyan New Drug Research Center Co., Ltd.
JOINN - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
assumes no liability for any loss arising out of or in reliance upon the whole or any part of the contents. Ren.
JOINN LABORATORIES (CHINA) CO., LTD.
Beijing Zhaoyan New Drug Research Center Co., Ltd.
(a joint stock limited company incorporated in the People's Republic of China) 6127 (Stock code: ) Overseas regulatory announcement
This announcement is made by Beijing Zhaoyan New Drug Research Center Co., Ltd. (the "Company") pursuant to a Hong Kong joint transaction 13.10B made in accordance with Article 1 of the Rules Governing the Listing of Securities of Limited by Share Ltd.
The announcement published by the Company on the website of the Shanghai Stock Exchange is set out below for reference only.
By order of the board of directors Beijing Zhaoyan New Drug Research Center Co., Ltd.
Feng Yuxia Chairman
2026 6 22 Beijing, China, year month day
As at the date of this announcement, the Board of Directors includes Ms. Feng Yuxia, Chairman and Executive Director, and Ms. Gao Da, Executive Director. Mr. Peng, Ms. Sun Yunxia, Mr. Gu Jingliang and Ms. Luo Feng, non-executive director Mr. Zhou Fengyuan, Independent non-executive directors Mr. Zhang Fan, Mr. Yang Changyun, Mr. Yang Fuquan and Mr. Ying Fangtian, and their respective Ms. Li Ye, Industrial Director.
Securities code: 603127 Securities abbreviation: Zhaoyan New Drug Announcement number: 2026-030
Beijing Zhaoyan New Drug Research Center Co., Ltd.
Announcement on the results of shareholder reduction of shares A
The company's board of directors, all directors and relevant shareholders guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and shall bear legal responsibility for the truthfulness, accuracy and completeness of its content.
Important content reminder:
Basic information on shareholders’ shareholdings
Before the announcement of the shareholding reduction plan on March 17, 2026, Beijing Zhaoyan New Drug Research Center Co., Ltd. The company (hereinafter referred to as the "Company") shareholder Gu Xiaolei and its person acting in concert Gu Meifang respectively hold the company's A shares.
20,420,504 shares and 10,322,035 shares, with shareholding ratios of 2.7251% and 1.3775% respectively. The above shares
It comes from other methods such as pre-IPO restricted shares and the company's capital reserve converted into shares.
Implementation results of the shareholding reduction plan
Gu Xiaolei and Gu Meifang disclosed the shareholding reduction plan on March 17, 2026. Since the date of the announcement of the shareholding reduction plan,
Within 3 months after the 3 trading days, shareholder Gu Xiaolei used centralized bidding through the Shanghai Stock Exchange The reduction of holdings shall not exceed 5,020,600 shares. The reduction of holdings shall not exceed 10,041,200 shares through block transactions. The total reduction of holdings shall be no more than 10,041,200 shares.
No more than 15,061,800 shares, no more than 2.01% of the company's total share capital; shareholder Gu Meifang passed the Shanghai Securities Exchange
Exchange will reduce its holdings by no more than 2,472,800 shares through centralized bidding and by block trading.
4,945,600 shares, a total reduction of no more than 7,418,400 shares, no more than 0.99% of the company's total share capital. Gu Xiao
Lei and his party acting in concert, Gu Meifang, reduced their holdings in total to no more than 3.00% of the company's total share capital. As of June 18, 2026, Gu Xiaolei and Gu Meifang had reduced their holdings of 15,061,800 shares and 7,418,400 shares respectively.
shares, the shareholding reduction plan has been implemented.
- Basic situation of the entities reducing their holdings before the reduction
Shareholder name Gu Xiaolei
Controlling shareholders, actual controllers and persons acting in concert □Yes √No
Shareholders directly holding more than 5% of the shares □Yes √No Shareholder status Directors and senior management □Yes √No Others: shareholders below 5%
Number of shares held: 20,420,504 shares
Shareholding ratio 2.7251%
Obtained before IPO: 6,900,600 shares Source of current shareholdings Acquired through other methods: 13,519,904 shares
Shareholder name Gu Meifang
Controlling shareholders, actual controllers and persons acting in concert □Yes √No
Shareholders directly holding more than 5% of the shares □Yes √No Shareholder status Directors, supervisors and senior managers □Yes √No Others: shareholders below 5%
Number of shares held: 10,322,035 shares
Shareholding ratio 1.3775%
Acquired before IPO: 4,721,800 shares Source of current shareholdings Acquired through other means: 5,600,235 shares
There are persons acting in concert among the above-mentioned reduction entities:
Number of shares held Name of shareholder, shareholding ratio, reason for formation of concerted action relationship (shares) Group 1 Gu Xiaolei 20,420,504 2.7251% Gu Xiaolei and Gu Meifang are aunt and nephew.
Gu Meifang 10,322,035 1.3775% Gu Xiaolei and Gu Meifang are aunt-nephew
Total 30,742,539 4.1026% —
- Implementation results of the shareholding reduction plan (1) Shareholders disclose the implementation results of the shareholding reduction plan due to the following matters:
The reduction plan has been implemented
Shareholder name Gu Xiaolei
The first disclosure date of the shareholding reduction plan is March 17, 2026
Number of shares reduced: 15,061,800 shares Holding reduction period April 7, 2026 to June 18, 2026
Reduce holdings through centralized bidding, 5,020,600 shares Ways to reduce holdings and corresponding quantity Large transaction reduction, 10,041,200 shares
The price range for holding reduction is 29.80~42.77 yuan/share The total amount of reduction is 363,166,125.27 yuan
Completion status of shareholding reduction Completed
Reduction ratio 2.01%
The original planned shareholding reduction ratio shall not exceed: 2.01%
Current number of shares held: 5,358,704 shares
Current shareholding ratio 0.715%
Shareholder name Gu Meifang
The first disclosure date of the shareholding reduction plan is March 17, 2026
Number of shares reduced: 7,418,400 shares
Holding reduction period April 10, 2026 to June 16, 2026
Reduce holdings through centralized bidding, 2,472,800 shares Ways to reduce holdings and corresponding quantity Large transaction reduction, 4,945,600 shares The price range for holding reduction is 29.80~41.75 yuan/share
The total amount of reduction is RMB 266,572,200
Completion status of shareholding reduction Completed
Reduction ratio 0.99%
The original planned shareholding reduction ratio shall not exceed: 0.99%
Current number of shares held: 2,903,635 shares Current shareholding ratio 0.387%
(2) Whether this shareholding reduction complies with relevant laws, regulations and the Exchange’s business rules √Yes □No
(3) Is the actual situation of this reduction consistent with the previously disclosed reduction plan and commitment? √Yes □No
(4) When the holding reduction time interval expires, has the holding reduction been implemented? □ Not implemented √ Implemented
(5) Whether the actual reduction has not reached the minimum reduction amount (proportion) of the reduction plan □ Not reached √ Reached
(6) Whether to terminate the shareholding reduction plan in advance □Yes √No
(7) Is there any violation of the shareholding reduction plan or other commitments □Yes √No
Announcement is hereby made.
Board of Directors of Beijing Zhaoyan New Drug Research Center Co., Ltd. June 23, 2026